Where Have All the New Drugs Gone
This article was originally published in RPM Report
Executive Summary
The drug approval drought keeps getting worse. FDA says it approved 20 new products during the year, one of the lowest totals in two decades. In fact, focusing on genuinely innovative medicines, the total was even worse. The good news is that 2006 should be a much better year. But focusing on 2006 misses the point: it's the long-term trend that matters. The hope for a turnaround relies on some leaps of faith. Industry is gambling that advances in drug development science will pay off-even though the first efforts to reap the fruits of the genomics revolution are one reason for the current drought.
You may also be interested in...
A Better Year for Drug Approvals? Not Really
By FDA's count, novel drug approvals were up more than 30% in 2008, to a respectable 24. Unfortunately, the number of Innovative Commercial Therapies was no better than it has been for the past four years. But it could have been worse.
The Blockbuster Bubble: What is the Real Trend in R&D Output?
The years 1996 and 1997 were terrific for the biopharmaceutical industry, with record numbers of new product approvals. It is now clear, though, that they were outliers from the historic rates of new product flow. That fact has important implications: the products approved in those years are the blockbusters industry is still living on, and they supported massive infrastructure that Big Pharma now needs to shed.
Leads and Contacts 0208
FDA Office of New Drugs Director John Jenkins has 17 drug divisions that report to him. These are the divisions and current directors.